Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

@article{CharlesNault2013CorrigendumHF,
  title={Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions},
  author={Jean Charles Nault and Maxime Mallet and Camilla Pilati and Julien Calderaro and Paulette Bioulac-Sage and Christophe Laurent and Alexis Laurent and Daniel Cherqui and Charles Balabaud and Jessica Zucman‐Rossi},
  journal={Nature Communications},
  year={2013},
  volume={4}
}
Somatic mutations activating telomerase reverse-trancriptase promoter were recently identified in several tumour types. Here we identify frequent similar mutations in human hepatocellular carcinomas (59%), cirrhotic preneoplastic macronodules (25%) and hepato-cellular adenomas with malignant transformation in hepatocellular carcinomas (44%). In hepatocellular tumours, telomerase reverse-transcripase-and CTNNB1-activating mutations are significantly associated. Moreover, preliminary data suggest… Expand

Figures and Tables from this paper

The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
TLDR
This study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features. Expand
Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors
TLDR
Investigation of whether TERT mutations can be detected in circulating cell‐free DNA of patients with HCC and/or cirrhosis found they are detectable in plasma cfDNA, and vitamin K2 was identified as an upstream regulator. Expand
The role of telomerase reverse transcriptase in human malignancies : genetic polymorphisms and promoter mutations
TLDR
The TERT SNP association with cancer risk has been extensively investigated, and it is observed that male individuals carrying the rs2736100_CC exhibited greater susceptibility to myeloproliferative neoplasms (MPNs), clonal diseases with myeloid cell origin (PAPER I). Expand
TERT promoter mutation during development of hepatoblastoma to hepatocellular carcinoma.
TLDR
It is demonstrated that periostin is highly expressed in MCD diet-induced NASH and that peruostin knockout mice show a markedly lower degree of steatosis, inflammation and fibrosis compared with wild type mice after being fed the MCD diets. Expand
Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits.
TLDR
The results define new hallmarks in molecular stratification and therapy options for patients at risk for HCC, and merit larger prospective investigations to develop a modified clinical-decision making algorithm based on the individualized next-generation sequencing analyses. Expand
Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma
TLDR
The identification of HBV and host variation associated with tumor initiation and progression has clinical utility for improving early diagnosis and prognosis; whereas the identification of somatic mutations driving tumorigenesis hold promise to inform precision treatment for HCC patients. Expand
Telomere Maintenance Mechanisms in Cancer
TLDR
The prevalence of TERTp mutations, TERT and TERC amplifications, and ALT amplifications in human tumours is portrayed, by organ/system and histotypes, to provide insights for screening, prognosis, and patient management stratification. Expand
Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma
Telomerase reverse transcriptase (TERT) promoter mutations are among the most frequent noncoding somatic mutations in multiple cancers, including hepatocellular carcinoma (HCC). The clinical andExpand
Understanding TERT Promoter Mutations: A Common Path to Immortality
TLDR
The fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation, are highlighted, along with germline variation in the TERT locus, which appear to have significant value as biomarkers of patient outcome. Expand
Hepatitis C virus-induced hepatocellular carcinoma
TLDR
Molecular biomarkers allowing further refinement of HCC risk are starting to be implemented in clinical platforms, allowing objective stratification of risk and leading to individualized therapy and surveillance for HCV individuals. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Lancet
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.
TLDR
The molecular 5-gene score is associated with outcomes of patients with HCC treated by resection in different clinical settings worldwide and should be tested in clinical trials to stratify patients in therapeutic decisions. Expand
Hepatocellular benign tumors-from molecular classification to personalized clinical care.
TLDR
The molecular pathways involved in benign hepatocyte proliferation are reviewed and how basic knowledge has been progressively translated into personalized clinical care is discussed. Expand
TERT Promoter Mutations in Familial and Sporadic Melanoma
TLDR
A melanoma-prone family through linkage analysis and high-throughput sequencing was investigated and a disease-segregating germline mutation in the promoter of the telomerase reverse transcriptase (TERT) gene, which encodes the catalytic subunit of telomersase, caused up to twofold increase in transcription. Expand
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
TLDR
TERT and ATRX mutations were mutually exclusive, suggesting that these two genetic mechanisms confer equivalent selective growth advantages and provide a biomarker that may be useful for the early detection of urinary tract and liver tumors and aid in the classification and prognostication of brain tumors. Expand
The Role of Telomeres in Stem Cells and Cancer
TLDR
Recent developments in understanding of the role of telomeres in replication stress and how telomerase expression in somatic stem cells may affect genome integrity control and carcinogenesis are discussed. Expand
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.
TLDR
This work identified for the first time the association between two rare diseases, MCA syndrome and HCA occurrence, but also that somatic GNAS-activating mutations in sporadic benign and malignant liver tumors are characterized by an inflammatory phenotype. Expand
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma
TLDR
Evidence is reported that suggests that the number of HBV integrations is associated with patient survival and copy-number variations were significantly increased at HBV breakpoint locations where chromosomal instability was likely induced. Expand
Human Telomerase Reverse Transcriptase (hTERT) Is a Novel Target of the Wnt/β-Catenin Pathway in Human Cancer*
TLDR
It is found that hTERT is a direct target of β-catenin·TCF4-mediated transcription and that the TCF4 binding site at the h TERT promoter is critical for β- catenin ·TCF 4-dependent expression regulation. Expand
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
TLDR
Functional analyses showed tumor suppressor properties for IRF2, whose inactivation, exclusively found in hepatitis B virus-related tumors, led to impaired TP53 function, and association of mutations in specific genes suggested that Wnt/β-catenin signaling might cooperate in liver carcinogenesis with both oxidative stress metabolism and Ras/mitogen-activated protein kinase (MAPK) pathways. Expand
...
1
2
3
4
...